Investigating initiating factors in neuroblastoma development from prevention to therapy (#108)

5:40 PM

Domenico Abruzzese

A Novel Zebrafish Xenotransplantation Model to Track Colorectal Cancer Metastasis. (#113)

5:40 PM

Faiza Basheer

Identification of checkpoint markers, cancer pathways and cancer genes in a mouse model of chronic colitis (#109)

5:40 PM

Vasso Apostolopoulos

Nuclear-encoded mitochondrial-associated genes as potential therapeutic targets for metastatic prostate cancer (#110)

5:40 PM

Jasmine M Bacon

Dual inhibition of KIF11 and BCL-XL or MCL-1 rewires mitotic cell fates and efficiently kills lung cancer cells (#111)

5:40 PM

Amar Balihodzic

­Investigating the biological mechanism of diffuse hemispheric glioma in hPSC-derived 3D brain organoids (#112)

5:40 PM

Patrick L Barry

CDK4/6 inhibitors and endocrine therapies induce senescence with drug- and cell line-specific vulnerabilities in ERα+ breast cancer (#114)

5:40 PM

Lena Batoon

Divergent patterns for genetic alterations drive pre-malignant clonal haematopoiesis in people with HIV (#115)

5:40 PM

Kiarash Behrouzfar

Characterization of TP53 X125 splice mutation and its role in cancer progression (#116)

5:40 PM

Apeksha Bhandarkar

Understanding how cancer cells adapt to changes in microenvironmental nutrient availability (#117)

5:40 PM

Alexandra A Birrell

Neurodevelopmental reprogramming of the cells-of-origin of diffuse midline glioma (#118)

5:40 PM

Jakarra A Brady

Deciphering netrin-1 implication in pancreatic cancer (#119)

5:40 PM

Nicolas Braissand

Targeting fibroblast growth factor (FGF)-fusions in previously untreatable cancers (#120)

5:40 PM

Nyah C Brooks

Beyond DNA-damage: the future of RNA-based cancer therapy for head and neck cancer (#121)

5:40 PM

Rikki A.M. Brown

Dysregulation of the tristetraprolin and NF-kappa B pathway contributes to estrogen receptor positive breast cancer treatment resistance. (#122)

5:40 PM

Mark D Bunting

Targeting subcellular JNK activity in pancreatic cancer (#123)

5:40 PM

Antonia Cadell

Investigating post-transcriptional responses to altered glucose availability in cancer (#124)

5:40 PM

Nicola E Caine

Understanding the clinical and molecular drivers of brain metastasis formation (#125)

5:40 PM

Bethany K Campbell

Exploring the functional and therapeutic impacts of cbl mutations in paediatric solid and brain tumours (#126)

5:40 PM

Katherine Camper

A whole genome CIRSPR screen to identify opportunities to overcome chemoresistance in pancreatic cancer (#127)

5:40 PM

Nuoyi Cao

Utilising CRISPR/Cas9 screening to uncover novel immunotherapies for targeting bone metastases in breast cancer (#128)

5:40 PM

Thomas Chadwick

Distinct 3D chromatin organisation underlies neuroendocrine plasticity in prostate cancer (#129)

5:40 PM

Dayna Challis

Utilising ex vivo models to explore the primary and metastatic microenvironment and uncover novel immune-targeted therapies.   (#130)

5:40 PM

Hugh Chalmers

Butyrate affected differentiation-, autophagy-, and cell cycle progression molecules in osteosarcoma cells partly via MEK/ERK signaling (#131)

5:40 PM

Mei-Chi Chang

Proteomic profiling of the tumor-invasive margin identifies GCHFR as a novel oncogenic regulator in hepatocellular carcinoma (#132)

5:40 PM

Zhili Cheng

Inhibition of oncogenic drivers induces redox stress and therapeutic resistance in non-small cell lung cancer (#133)

5:40 PM

Kimberley Clark

Mechanisms of oncogenic JNK signalling in metastatic triple-negative breast cancer (#134)

5:40 PM

Misaki S Clearwater

Spatial profiling reveals stromal-restricted immune infiltration and exclusion from tumour cores in Rhabdoid Tumours (#135)

5:40 PM

Erin Coll

B Cells and Tertiary Lymphoid Structures as Predictors of Prostate Cancer Outcomes (#136)

5:40 PM

Jessica Da Gama Duarte

Mapping the ligandable proteome of medulloblastoma for target-based drug discovery (#137)

5:40 PM

Montana Dalziel

Early detection of melanoma using circulating tumour-specific antibodies (#138)

5:40 PM

Tawany T De Carvalho Gil

Investigating the role of E. coli Nissle biofilm formation in colorectal cancer tumour colonization. (#139)

5:40 PM

Rebekah de Nys

A novel RNA binding protein (ZCCHC24) regulates breast cancer cell plasticity and metastasis (#140)

5:40 PM

Shruti Deshpande

Deciphering Mitotic and DNA Damage Pathways Driving Malignant Rhabdoid Tumour: Preclinical and Mechanistic Evaluation of Alisertib, Temozolomide, and Irinotecan Combination Therapy (#141)

5:40 PM

Kimberly Dias

Detecting changes in the tumour microenvironment and CAR T infiltration following chemotherapeutic priming using intravital imaging (#142)

5:40 PM

Marija Dinevska

Fatty acids drive ELF3-mediated neuroendocrine differentiation and progression in prostate cancer (#144)

5:40 PM

Ez Aldeen Esawi

Revolutionising leukaemia care: a non-invasive salivary-cytology-based screening (#145)

5:40 PM

Falak Fazal

A blueprint for mutation-defined hallmark vulnerabilities across human cancers (#146)

5:40 PM

Yuchen Feng

Repurposing the cardiac glycoside digoxin as a targeted treatment for SMARCA4-mutant ovarian cancer (#147)

5:40 PM

Natisha R Field

Personalized Treatment Strategies Guided by Exacta Multi-Omics Profiling in Advanced Refractory Head and Neck Squamous Cell Carcinoma (SCCHN) (#148)

5:40 PM

Joachim Fluhrer

Transcriptional patterns reveal heterogeneous trajectories underlying metastatic progression in prostate cancer (#149)

5:40 PM

Yunfan Fu

Ex Vivo Drug Efficacy in High-Risk Paediatric Cancers: A Comprehensive Analysis of the ZERO Cohort (#150)

5:40 PM

Luke LF Fuller

The development of a novel cell-based screening tool to reduce the impact of bowel cancer across the community. (#151)

5:40 PM

Allegra Chajinsi Gaza

Tuning CAR T cell response with TNFAIP3 variants (#152)

5:40 PM

Caroline Giardina

Identifying and targeting FOLFIRINOX resistance mechanisms to improve outcomes in pancreatic cancer (#153)

5:40 PM

Katie Gordon

A blood-based biomarker study of rare cancer patients undergoing combination immunotherapy (#154)

5:40 PM

Eliza Grills

Induction of interferon signalling dictates Menin inhibitor efficacy in NPM1-mutant AML (#155)

5:40 PM

Emily Gruber

Direct targeting of quiescent cancer stem cells (#156)

5:40 PM

Jessica Hart

Targeting the interplay between the Replication Stress-induced DNA Damage Response and Epigenetics for children with High-Risk Neuroblastoma (#157)

5:40 PM

Hannah E Hartley

Utilising Cas gene editing systems to identify non-coding lncRNA dependencies in high-risk MLL-rearranged acute myeloid leukaemia (#158)

5:40 PM

Steven He

Targeting the NPY/NPY1R signaling axis impairs metastasis and tissue wasting in pancreatic cancer (#159)

5:40 PM

David Herrmann

Stimulation of androgen receptor signalling has therapeutic efficacy in estrogen receptor positive breast tumours of no special type and of the lobular special type (#160)

5:40 PM

Theresa E Hickey

MoLBi: From Theatre to Therapy – Building Australia’s First Live-Biobanking Platform for Precision Immunotherapy (#161)

5:40 PM

Gwo Yaw Ho

CAM-on-MoLBi: A Rapid and Scalable In Ovo Platform for Translational Cancer Modelling (#162)

5:40 PM

Gwo Yaw Ho

Mechanistic deconvolution reveals DHODH as the key target of the KDM4 inhibitor QC6352​ (#163)

5:40 PM

Jacinda JH Holtsmark

Endogenous isoform-specific CSF-1 signalling determines monocytic AML differentiation therapy response (#164)

5:40 PM

Samin Iranfar

ProSLeM: A Novel Computational Platform to Accelerate Synthetic Lethality-Based Treatments for Prostate Cancer (#165)

5:40 PM

Mohammad A. Ismail

High-throughput single-cell lentiviral integration mapping to enhance CAR T Cell safety and efficacy (#166)

5:40 PM

Jafar S Jabbari

Regulation of AKR1Cs’ expression of SAS oral cancer cells by areca nut and arecoline (#167)

5:40 PM

Jiiang-Huei Jeng

PRDM9-Mediated H3K4me3 Drives Cholesterol Metabolic Gene Expression and Chemotherapy Tolerance in Glioblastoma (#168)

5:40 PM

George L Joun

seg (#169)

5:40 PM

Narasimha Raju Kalidindi

Spatial transcriptomics reveals heterogeneity and microenvironmental shifts in breast cancer subtypes and metastatic progression (#170)

5:40 PM

Narasimharaju Kalidindi

A phase I/II study to assess the toxicity and preliminary efficacy of SUBA-itraconazole and dual checkpoint inhibitor cadonilimab as maintenance therapy in advanced pancreatic ductal adenocarcinoma (#171)

5:40 PM

Bratati Karmakar

Histone methyltransferase PRDM9 promotes survival of drug-tolerant persister cells in glioblastoma (#172)

5:40 PM

Emma G Kempe

Investigating the role of neutrophils in colorectal cancer metastasis using zebrafish xenotransplantation model (#173)

5:40 PM

Ali Khalafizadeh

CAR-extracellular vesicles (CAR-EVs) as a scalable cell-free immunotherapy for triple-negative breast cancer (#174)

5:40 PM

Ramin Khanabdali

A comprehensive multiomics atlas of treatment-naïve breast cancer uncovers co-occurring tumor–immune ecosystems driving immune hot and cold phenotypes (#175)

5:40 PM

Hani Kim

From cells to circuits: decoding rare breast cancer ecosystems (#176)

5:40 PM

Somi Kordafshari

Targeting the epigenetic adaptor protein menin in multiple myeloma (#177)

5:40 PM

Sree Kumar

Moonlighting function of the GTP producing enzyme IMPDH2 in melanoma suppression (#178)

5:40 PM

Gamze Kuser Abali